GSK and Ionis reported that bepirovirsen, an antisense oligonucleotide, met primary endpoints in two pivotal Phase 3 trials and achieved functional cure rates in chronic hepatitis B patients. The companies said they plan global regulatory filings based on the data and described the results as a potential paradigm shift beyond life‑long viral suppression. Both firms did not immediately release full datasets, but said the trials reached statistical and clinically meaningful thresholds for sustained HBsAg loss after treatment. GSK and Ionis signaled the combination of antisense technology with antiviral platforms could enable a finite course of therapy for some CHB patients. Regulatory filings and independent review will determine the next steps; if confirmed, a labeled functional cure would be a major milestone in chronic hepatitis B therapeutics and could prompt rapid uptake in markets with high unmet need.